4//SEC Filing
Naider Avi Z. 4
Accession 0001567619-19-004574
CIK 0001581720other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 9:16 AM ET
Size
18.8 KB
Accession
0001567619-19-004574
Insider Transaction Report
Form 4
Naider Avi Z.
Director
Transactions
- Gift
Common Stock
2019-01-31−15,000→ 111,843 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2019-02-15$235.00/sh−15,625$3,671,875→ 0 totalExercise: $13.00Exp: 2024-07-30→ Common Stock (15,625 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2019-02-15$235.00/sh−11,000$2,585,000→ 0 totalExercise: $78.58Exp: 2027-06-21→ Common Stock (11,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2019-02-15$235.00/sh−8,750$2,056,250→ 0 totalExercise: $180.98Exp: 2028-06-12→ Common Stock (8,750 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2019-02-15$235.00/sh−7,812$1,835,820→ 0 totalExercise: $20.91Exp: 2025-07-27→ Common Stock (7,812 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2019-02-15$235.00/sh−7,812$1,835,820→ 0 totalExercise: $24.18Exp: 2026-06-09→ Common Stock (7,812 underlying) - Disposition to Issuer
Common Stock
2019-02-15$235.00/sh−111,843$26,283,105→ 0 total
Footnotes (3)
- [F1]Represents the number of shares of Issuer's common stock that were donated as a charitable contribution. The reporting person does not exercise voting or dispositive powers, directly or indirectly, over the donated shares following this transfer.
- [F2]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
- [F3]Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Documents
Issuer
Loxo Oncology, Inc.
CIK 0001581720
Entity typeother
Related Parties
1- filerCIK 0001612217
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 9:16 AM ET
- Size
- 18.8 KB